KR102326482B1 - 피부과학적 병리의 치료 - Google Patents

피부과학적 병리의 치료 Download PDF

Info

Publication number
KR102326482B1
KR102326482B1 KR1020207036672A KR20207036672A KR102326482B1 KR 102326482 B1 KR102326482 B1 KR 102326482B1 KR 1020207036672 A KR1020207036672 A KR 1020207036672A KR 20207036672 A KR20207036672 A KR 20207036672A KR 102326482 B1 KR102326482 B1 KR 102326482B1
Authority
KR
South Korea
Prior art keywords
human
mab
subject
antibody
mabp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020207036672A
Other languages
English (en)
Korean (ko)
Other versions
KR20200145844A (ko
Inventor
존 시마드
Original Assignee
엑스바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스바이오테크 인코포레이티드 filed Critical 엑스바이오테크 인코포레이티드
Publication of KR20200145844A publication Critical patent/KR20200145844A/ko
Application granted granted Critical
Publication of KR102326482B1 publication Critical patent/KR102326482B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207036672A 2011-04-01 2012-04-02 피부과학적 병리의 치료 Expired - Fee Related KR102326482B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161470538P 2011-04-01 2011-04-01
US61/470,538 2011-04-01
KR1020197021295A KR20190090046A (ko) 2011-04-01 2012-04-02 피부과학적 병리의 치료
PCT/US2012/031803 WO2012135812A2 (en) 2011-04-01 2012-04-02 Treatment for dermatological pathologies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197021295A Division KR20190090046A (ko) 2011-04-01 2012-04-02 피부과학적 병리의 치료

Publications (2)

Publication Number Publication Date
KR20200145844A KR20200145844A (ko) 2020-12-30
KR102326482B1 true KR102326482B1 (ko) 2021-11-17

Family

ID=46927554

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197021295A Ceased KR20190090046A (ko) 2011-04-01 2012-04-02 피부과학적 병리의 치료
KR1020137028813A Expired - Fee Related KR102004554B1 (ko) 2011-04-01 2012-04-02 피부과학적 병리의 치료
KR1020207036672A Expired - Fee Related KR102326482B1 (ko) 2011-04-01 2012-04-02 피부과학적 병리의 치료

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020197021295A Ceased KR20190090046A (ko) 2011-04-01 2012-04-02 피부과학적 병리의 치료
KR1020137028813A Expired - Fee Related KR102004554B1 (ko) 2011-04-01 2012-04-02 피부과학적 병리의 치료

Country Status (11)

Country Link
US (2) US20120251548A1 (enExample)
EP (2) EP2694107B1 (enExample)
JP (2) JP6062918B2 (enExample)
KR (3) KR20190090046A (enExample)
CN (2) CN103442733A (enExample)
AU (2) AU2012236106B2 (enExample)
CA (1) CA2831126C (enExample)
DK (1) DK2694107T3 (enExample)
ES (1) ES2697056T3 (enExample)
PT (1) PT2694107T (enExample)
WO (1) WO2012135812A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011268229B2 (en) 2010-06-18 2015-04-16 Xbiotech Inc. Arthritis treatment
ES2622482T3 (es) 2010-08-23 2017-07-06 Xbiotech, Inc Tratamiento de enfermedades neoplásicas
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
KR20190090046A (ko) * 2011-04-01 2019-07-31 엑스바이오테크, 인크. 피부과학적 병리의 치료
CN108404127B (zh) 2011-09-23 2025-12-12 埃克斯生物科技公司 恶病质治疗
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
AU2013327498B2 (en) * 2012-10-04 2018-06-28 Janssen Biotech, Inc. Treatment of psychiatric conditions
SG11201907159SA (en) 2017-02-16 2019-09-27 Xbiotech Inc Treatment of hidradenitis suppurativa
CN115702023A (zh) * 2020-04-16 2023-02-14 詹森生物科技公司 化脓性汗腺炎的治疗
CA3095675A1 (en) * 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024917A1 (en) * 1994-03-15 1995-09-21 Unilever Plc Skin treatment composition
WO2010030979A2 (en) * 2008-09-12 2010-03-18 Xbiotech, Inc. Targeting pathogenic monocytes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
CA2147151A1 (en) 1992-10-14 1994-04-28 Robert A. Snow Therapeutic and diagnostic imaging compositions and methods
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5945576A (en) * 1996-04-05 1999-08-31 Brigham & Women's Hospital, Inc. Mouse model of psoriasis
CA2426384A1 (en) 2000-10-19 2003-04-17 Kyowa Hakko Kogyo Co., Ltd. Antibody inhibiting vplf activity
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US20050276807A1 (en) * 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
RS54163B1 (sr) 2006-05-30 2015-12-31 Genentech Inc. Anti-cd22 antitela, njihovi imunokonjugati i njihova upotreba
WO2008082651A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
CN102112154B (zh) * 2008-05-30 2013-10-30 埃克斯生物科技公司 白细胞介素-1α抗体及使用方法
CA2749966A1 (en) * 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins
JP5866130B2 (ja) * 2010-09-10 2016-02-17 アペクシジェン， インコーポレイテッド 抗ＩＬ−１β抗体およびその使用方法
KR20190090046A (ko) * 2011-04-01 2019-07-31 엑스바이오테크, 인크. 피부과학적 병리의 치료
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024917A1 (en) * 1994-03-15 1995-09-21 Unilever Plc Skin treatment composition
WO2010030979A2 (en) * 2008-09-12 2010-03-18 Xbiotech, Inc. Targeting pathogenic monocytes

Also Published As

Publication number Publication date
CN110201157A (zh) 2019-09-06
EP2694107B1 (en) 2018-08-22
EP2694107A4 (en) 2014-10-01
PT2694107T (pt) 2018-11-27
KR102004554B1 (ko) 2019-10-01
CN103442733A (zh) 2013-12-11
JP6453278B2 (ja) 2019-01-16
KR20190090046A (ko) 2019-07-31
WO2012135812A3 (en) 2013-01-31
ES2697056T3 (es) 2019-01-21
AU2017201201B2 (en) 2018-12-13
US20160368982A1 (en) 2016-12-22
CA2831126C (en) 2019-11-12
US9902769B2 (en) 2018-02-27
JP6062918B2 (ja) 2017-01-18
EP2694107A2 (en) 2014-02-12
AU2012236106A1 (en) 2013-09-26
US20120251548A1 (en) 2012-10-04
DK2694107T3 (en) 2018-12-10
AU2017201201A1 (en) 2017-04-06
CA2831126A1 (en) 2012-10-04
AU2012236106B2 (en) 2016-12-08
JP2014509662A (ja) 2014-04-21
KR20140033036A (ko) 2014-03-17
KR20200145844A (ko) 2020-12-30
JP2017014228A (ja) 2017-01-19
EP3417879A1 (en) 2018-12-26
WO2012135812A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
KR102326482B1 (ko) 피부과학적 병리의 치료
US11191831B2 (en) Treatment of psychiatric conditions
KR102167261B1 (ko) 관절염 치료
JP2022177132A (ja) 精神障害の治療
HK40013773A (zh) 皮肤病学病状的治疗
HK1187260A (en) Treatment for dermatological pathologies

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241110

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241110

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241110